Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

BACKGROUND: The effectiveness of SARS-CoV-2 vaccines in older adults living in long-term care facilities is uncertain. We investigated the protective effect of the first dose of the Oxford-AstraZeneca non-replicating viral-vectored vaccine (ChAdOx1 nCoV-19; AZD1222) and the Pfizer-BioNTech mRNA-base...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Lancet Infect Dis
Κύριοι συγγραφείς: Shrotri, Madhumita, Krutikov, Maria, Palmer, Tom, Giddings, Rebecca, Azmi, Borscha, Subbarao, Sathyavani, Fuller, Christopher, Irwin-Singer, Aidan, Davies, Daniel, Tut, Gokhan, Lopez Bernal, Jamie, Moss, Paul, Hayward, Andrew, Copas, Andrew, Shallcross, Laura
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Elsevier Science ;, The Lancet Pub. Group 2021
Θέματα:
Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8221738/
https://ncbi.nlm.nih.gov/pubmed/34174193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(21)00289-9
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια